Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Am J Kidney Dis ; 68(5): 782-788, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27555106

ABSTRACT

BACKGROUND: The choice for either kidney or combined liver-kidney transplantation in young people with kidney failure and liver fibrosis due to autosomal recessive polycystic kidney disease (ARPKD) can be challenging. We aimed to analyze the characteristics and outcomes of transplantation type in these children, adolescents, and young adults. STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: We derived data for children, adolescents, and young adults with ARPKD with either kidney or combined liver-kidney transplants for 1995 to 2012 from the ESPN/ERA-EDTA Registry, a European pediatric renal registry collecting data from 36 European countries. FACTOR: Liver transplantation. OUTCOMES & MEASUREMENTS: Transplantation and patient survival. RESULTS: 202 patients with ARPKD aged 19 years or younger underwent transplantation after a median of 0.4 (IQR, 0.0-1.4) years on dialysis therapy at a median age of 9.0 (IQR, 4.1-13.7) years. 32 (15.8%) underwent combined liver-kidney transplantation, 163 (80.7%) underwent kidney transplantation, and 7 (3.5%) were excluded because transplantation type was unknown. Age- and sex-adjusted 5-year patient survival posttransplantation was 95.5% (95% CI, 92.4%-98.8%) overall: 97.4% (95% CI, 94.9%-100.0%) for patients with kidney transplantation in contrast to 87.0% (95% CI, 75.8%-99.8%) with combined liver-kidney transplantation. The age- and sex-adjusted risk for death after combined liver-kidney transplantation was 6.7-fold (95% CI, 1.8- to 25.4-fold) greater than after kidney transplantation (P=0.005). Five-year death-censored kidney transplant survival following combined liver-kidney and kidney transplantation was similar (92.1% vs 85.9%; P=0.4). LIMITATIONS: No data for liver disease of kidney therapy recipients. CONCLUSIONS: Combined liver-kidney transplantation in ARPKD is associated with increased mortality compared to kidney transplantation in our large observational study and was not associated with improved 5-year kidney transplant survival. Long-term follow-up of both kidney and liver involvement are needed to better delineate the optimal transplantation strategy.


Subject(s)
Kidney Transplantation , Liver Cirrhosis/etiology , Liver Cirrhosis/surgery , Liver Transplantation , Polycystic Kidney, Autosomal Recessive/complications , Renal Insufficiency/etiology , Renal Insufficiency/surgery , Adolescent , Child , Child, Preschool , Cohort Studies , Female , Humans , Infant , Liver Cirrhosis/mortality , Male , Polycystic Kidney, Autosomal Recessive/mortality , Registries , Renal Insufficiency/mortality , Societies, Medical , Survival Analysis
2.
Pediatr Nephrol ; 31(5): 833-41, 2016 May.
Article in English | MEDLINE | ID: mdl-26692024

ABSTRACT

BACKGROUND: Chronic haemodialysis (HD) in small children has not been adequately investigated. METHODS: This was a retrospective investigation of the use of chronic HD in 21 children aged <2 years (n = 12 aged <1 year) who were registered in the Italian Pediatric Dialysis Registry. Data collected over a period of >10 years were analysed. RESULTS: The median age of the 21 children at start of HD was 11.4 [interquartile range (IQR) 6.2-14.6] months, and HD consisted mainly of haemodiafiltration for 3-4 h in ≥4 sessions/week. A total of 51 central venous catheters were placed, and the median survival of tunnelled and temporary lines was 349 and 31 days, respectively (p < 0.001). Eight children (38 %) showed evidence of central vein thrombosis. Although 19 % of patients received growth hormone and 63.6 % received enteral feeding, the weight and height of these patients remained suboptimal. During the HD period the haemoglobin level increased in all patients, but not to normal levels (from 8.5 to 9.6 g/dl) despite erythropoietin administration (503-600 U/kg/week). The hospitalisation rate was 1.94/patient-year. Seventeen patients underwent renal transplantation at a median age of 3.0 years. Four patients, all affected by severe comorbidities, died during follow-up (in 2 cases due to absence of a vascular access). The 5- and 10-year cumulative survival was 82.4 and 68.7 %, respectively. CONCLUSIONS: Extracorporeal dialysis is feasible in children aged <2 years, but comorbidities, vascular access, growth and anaemia remain major concerns.


Subject(s)
Catheterization, Central Venous , Hemodiafiltration , Kidney Failure, Chronic/therapy , Renal Dialysis , Age Factors , Anemia/etiology , Body Height , Catheterization, Central Venous/adverse effects , Catheterization, Central Venous/instrumentation , Catheterization, Central Venous/mortality , Catheters, Indwelling , Central Venous Catheters , Child Development , Child, Preschool , Comorbidity , Disease Progression , Feasibility Studies , Female , Hemodiafiltration/adverse effects , Hospitalization , Humans , Infant , Italy , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/mortality , Kidney Transplantation , Male , Registries , Renal Dialysis/adverse effects , Renal Dialysis/mortality , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , Weight Gain
3.
BMC Nephrol ; 15: 41, 2014 Mar 03.
Article in English | MEDLINE | ID: mdl-24589093

ABSTRACT

BACKGROUND: Schimke immuno-osseous dysplasia (SIOD, OMIM #242900) is an autosomal-recessive pleiotropic disorder characterized by spondyloepiphyseal dysplasia, renal dysfunction and T-cell immunodeficiency. SIOD is caused by mutations in the gene SMARCAL1. CASE PRESENTATION: We report the clinical and genetic diagnosis of a 5-years old girl with SIOD, referred to our Center because of nephrotic-range proteinuria occasionally detected during the follow-up for congenital hypothyroidism. Mutational analysis of SMARCAL1 gene was performed by polymerase chain reaction (PCR) and bidirectional sequencing. Sequence analysis revealed that patient was compound heterozygous for two SMARCAL1 mutations: a novel missense change (p.Arg247Pro) and a well-known nonsense mutation (p.Glu848*). CONCLUSION: This report provided the clinical and genetic description of a mild phenotype of Schimke immuno-osseous dysplasia associated with nephrotic proteinuria, decreasing after combined therapy with ACE inhibitors and sartans. Our experience highlighted the importance of detailed clinical evaluation, appropriate genetic counseling and molecular testing, to provide timely treatment and more accurate prognosis.


Subject(s)
Arteriosclerosis/diagnosis , Arteriosclerosis/genetics , DNA Helicases/genetics , Genetic Predisposition to Disease/genetics , Immunologic Deficiency Syndromes/diagnosis , Immunologic Deficiency Syndromes/genetics , Nephrotic Syndrome/diagnosis , Nephrotic Syndrome/genetics , Osteochondrodysplasias/diagnosis , Osteochondrodysplasias/genetics , Polymorphism, Single Nucleotide/genetics , Pulmonary Embolism/diagnosis , Pulmonary Embolism/genetics , Child, Preschool , Female , Humans , Mutation/genetics , Phenotype , Primary Immunodeficiency Diseases
4.
Nephrol Dial Transplant ; 28(6): 1603-9, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23585587

ABSTRACT

BACKGROUND: Paediatric literature about encapsulating peritoneal sclerosis (EPS) is limited and comes primarily from anecdotic experiences. In this study, we described the incidence and characteristics of EPS in a large paediatric chronic peritoneal dialysis (CPD) patient population. METHODS: We reviewed files of patients starting CPD at <16 years of age, recorded from January 1986 to December 2011 by the Italian Registry of Pediatric Chronic Dialysis (n = 712). Moreover, in December 2011, a survey was performed involving all the Italian Pediatric Nephrology Units to report such EPS cases that occurred after CPD withdrawal. RESULTS: Fourteen EPS cases were reported, resulting in a prevalence of 1.9%. The median age of EPS cases was 4.8 years (range 0.6-14.4) at the start of CPD and 14.3 years (6.5-26.8) at EPS diagnosis. Eleven EPS cases received CPD for longer than 5 years. At diagnosis, nine patients were still on CPD, two were on haemodialysis and three were transplanted. In eight patients, the primary renal disease was represented by glomerulopathy, mainly focal segmental glomerulosclerosis (n = 5). In the last 6 months prior to CPD discontinuation, 10 patients were treated with solutions containing more than 2.27% glucose. Peritonitis incidence was 1:26.8 CPD-months, similar to that calculated in children >12 months of age from the same registry (1:28.3 CPD-months). The mortality rate was 43%. A more aggressive course and an association with calcineurin inhibitors were observed in transplanted patients. CONCLUSIONS: Surveillance for EPS should be maintained in high-risk children who received long-term PD even after years from CPD withdrawal.


Subject(s)
Peritoneal Dialysis/adverse effects , Peritoneal Fibrosis/etiology , Peritonitis/etiology , Renal Insufficiency, Chronic/complications , Adolescent , Child , Child, Preschool , Female , Humans , Incidence , Infant , Infant, Newborn , Italy/epidemiology , Male , Peritoneal Dialysis/mortality , Peritoneal Fibrosis/epidemiology , Peritoneal Fibrosis/mortality , Peritonitis/epidemiology , Peritonitis/mortality , Prognosis , Registries , Retrospective Studies , Risk Factors , Survival Rate
5.
Pediatrics ; 130(5): e1385-8, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23027168

ABSTRACT

Genetic mutations in complement components are associated with the development of atypical hemolytic uremic syndrome (aHUS), a rare disease with high morbidity rate triggered by infections or unidentified factors. The uncontrolled activation of the alternative pathway of complement results in systemic endothelial damage leading to progressive development of renal failure. A previously healthy 8-month-old boy was referred to our hospital because of onset of fever, vomiting, and a single episode of nonbloody diarrhea. Acute kidney injury with preserved diuresis, hemolytic anemia, and thrombocytopenia were detected, and common protocols for management of HUS were followed without considerable improvement. The persistent low levels of complement component C3 led us to hypothesize the occurrence of aHUS. In fact, the child carried a specific mutation in complement factor H (Cfh; nonsense mutation in 3514G>T, serum levels of Cfh 138 mg/L, normal range 350-750). Given the lack of response to therapy and the occurrence of kidney failure requiring dialysis, we used eculizumab as rescue therapy, a monoclonal humanized antibody against the complement component C5. One week from the first administration, we observed a significant improvement of all clinical and laboratory parameters with complete recovery from hemodialysis, even in the presence of systemic infections. Our case report shows that complement inhibiting treatment allows the preservation of renal function and avoids disease relapses during systemic infections.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Hemolytic-Uremic Syndrome/drug therapy , Kidney/physiology , Atypical Hemolytic Uremic Syndrome , Humans , Infant , Male
6.
G Ital Nefrol ; 29 Suppl 54: S125-9, 2012.
Article in Italian | MEDLINE | ID: mdl-22388843

ABSTRACT

Apheresis procedures are used in children to treat an increasing number of conditions by removing different types of substances from the bloodstream. In a previous study we evaluated the first results of our experience in children, emphasizing the solutions adopted to overcome technical difficulties and to adapt adult apheresis procedures to a pediatric population. The aim of the present study is to present data on a larger number of patients in whom apheresis was the main treatment. Ninety-three children (50 m, 43 f) affected by renal and/or extrarenal diseases were included. They were treated with LDL apheresis, protein A immunoadsorption, or plasma exchange. Our therapeutic protocol was the same as described in the previous study. Renal diseases and immunological disorders remained the most common conditions requiring this therapeutic approach. However, hemolytic uremic syndrome (HUS) was no longer the most frequent renal condition to be treated, as apheresis is currently the first treatment option only in cases of atypical HUS. In this series we also treated small children, showing that low weight should no longer be considered a contraindication to apheresis procedures. The low rate of complications and the overall satisfactory clinical results with increasingly advanced technical procedures make a wider use of apheresis in children realistic in the years to come.


Subject(s)
Blood Component Removal , Immune System Diseases/therapy , Kidney Diseases/therapy , Adolescent , Anemia, Hemolytic, Autoimmune/therapy , Blood Component Removal/methods , Child , Child, Preschool , Female , Hemolytic-Uremic Syndrome/therapy , Humans , Infant , Lipoproteins, LDL/blood , Liver Failure, Acute/therapy , Lupus Erythematosus, Systemic/therapy , Male , Metabolic Diseases/therapy , Nervous System Diseases/therapy , Retrospective Studies , Treatment Outcome , Vasculitis/therapy
7.
Pediatr Radiol ; 37(7): 674-7, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17520246

ABSTRACT

BACKGROUND: Contrast-enhanced voiding urosonography (VUS) is becoming more widely used for the diagnosis of vesicoureteric reflux (VUR), but until now its use has only been accepted for first diagnosis in females and in the follow-up of children, including boys, who have already undergone voiding cystourethrography (VCUG). OBJECTIVE: To describe our 6-year experience with VUS used as a first step in the diagnosis of VUR. MATERIALS AND METHODS: A total of 610 children (334 boys, 276 girls; mean age 22 months), underwent VUS as the first step in the diagnosis of VUR. In selected children, VCUG was also performed. RESULTS: VUR was detected in 199 of 610 VUS examinations, and 265 refluxing kidney-ureter units were found. Children with VUR underwent antibiotic prophylaxis or surgery. Children without VUR underwent clinical follow-up. Just 60 children underwent VCUG. The criteria for VCUG were: high-grade VUR after consultation with a urologist, onset of urinary tract infection while receiving prophylaxis, nondiagnostic VUS, and other malformations with or without clinical signs. CONCLUSION: Our experience suggests that we can use VUS as the first step in the diagnosis of VUR in children, boys and girls, with a significant reduction in radiation exposure.


Subject(s)
Vesico-Ureteral Reflux/diagnostic imaging , Chi-Square Distribution , Contrast Media , Female , Humans , Infant , Male , Phospholipids , Prospective Studies , Sensitivity and Specificity , Sulfur Hexafluoride , Ultrasonography , Urination
SELECTION OF CITATIONS
SEARCH DETAIL
...